# P6 Discussion, Limitations, and Conclusion Report

## Execution identity and repository baseline

| Field | Value |
|---|---|
| Stage | P6 -- Discussion, Limitations, and Conclusion |
| Model | Sol-high |
| Reasoning effort | High |
| Canonical plan | `thesis-writing/paper-aaai/clinicause_aaai27_paper_operational_plan_v1.1.md` |
| Canonical plan version | 1.1, dated 2026-07-19 |
| Canonical plan SHA-256 | `8df13e88892da8cd0d78df33e0b7a997983d95f99222de0eb9605426e905b1c1` |
| Current HEAD before work | `47f487c84a92f0a0b6a8271b370ff9d7afcace23` (`AAAI P5`) |
| Branch | `main` |
| Accepted P5 commit | `47f487c84a92f0a0b6a8271b370ff9d7afcace23` |

The last six commits inspected before editing were `47f487c` (`AAAI P5`),
`b604d68` (`AAAI p4`), `14337a2` (`AAAI P3`), `a851e38` (`docs: record P3
commit evidence`), `6050404` (`paper: draft dataset construction and
validation`), and `884ff8e` (`AAAI skeleton`). The statistics for `HEAD` and
`HEAD~1` and both nested-repository revisions were inspected. The worktree
initially contained a modified `prompt.txt` and the untracked Version 1.1 plan;
both were pre-existing user work and were protected. Repository cleanup remains
deferred by user decision.

The revised P6--P10 workflow was followed. Version 1.1 was used exclusively for
stage definitions; the old sequence was not combined with it.

## Sources inspected

The following sources were read before drafting:

- the complete Version 1.1 operational plan;
- the complete `paper.tex`, `paper_evidence_map.md`,
  `paper_build_report.md`, and `reports/P5_results_report.md`;
- thesis Chapters 11 (`Discussion`) and 12 (`Conclusions and Future Work`);
- `results_source_packet.md` and `results_decision_register.md`;
- checked cohort, predictive, CATE, matching, matching-failure, sensitivity,
  and permutation records referenced by P5, together with their manifest and
  checksum context;
- `reproducibility/provenance_gaps.csv`; and
- `audit/llm_prompt_provenance_audit.md`.

P5's numerical analysis was treated as scientifically accepted and was not
reopened. No patient-level data, experiment, model run, estimator run,
permutation, sensitivity analysis, or new literature search was performed.

## Files changed

P6 changed or created only the authorized scientific artifacts:

1. `thesis-writing/paper-aaai/paper.tex`
2. `thesis-writing/paper-aaai/paper.pdf`
3. `thesis-writing/paper-aaai/paper_build_report.md`
4. `thesis-writing/paper-aaai/paper_evidence_map.md`
5. `thesis-writing/paper-aaai/reports/P6_discussion_conclusion_report.md`

Compilation regenerated the already tracked `paper.aux` and
`paper.fdb_latexmk` files under the deferred-cleanup policy. No Abstract,
Introduction, Related Work, Section 3--5 prose, figure, result table,
bibliography, code, checked evidence, thesis source, or operational-plan file
was edited.

## Discussion and Conclusion outcome

### Structure, counts, and footprint

Discussion contains five substantive paragraphs organized under four compact
subsections:

1. `Resource Utility and Cross-Dataset Portability` -- two paragraphs;
2. `Estimator Triangulation and CausalPFN` -- one paragraph;
3. `LLM-Assisted Design and Future Research` -- one paragraph; and
4. `Limitations` -- one concentrated paragraph.

The Conclusion is exactly one compact paragraph. LaTeX-stripped prose contains
561 Discussion words and 79 Conclusion words, 640 combined, excluding section
and subsection headings. Discussion begins on page 5 at approximately
536.22 pt from the page top, continues through the left column of page 6 and a
short portion of its right column, and Conclusion ends before References at
approximately 259.55 pt. Equivalent two-column occupancy is approximately
0.94 physical AAAI page, within the requested 0.80--1.10-page budget.

The manuscript is seven pages at this stage. Technical content ends on page 6;
page 7 contains only the final continuation of References. Empty Abstract and
placeholder Introduction/Related Work text remain for P7, so page-budget
pressure will need reassessment during P9 compression, but the current layout
retains a viable path to the seven-page technical-content limit without global
P6 compression or formatting changes.

### Resource reuse and portability interpretation

The Discussion leads positively with the main contribution: reusable analytical
resources, not merely final effect tables. It explains how explicit interfaces
support alternative estimators and temporal representations, replaceable proxy
states and graphs, cohort/support studies, lineage audit, and reuse of
estimator-ready tables without rebuilding every integration stage. These are
interface-supported research uses, not public-availability claims.

Cross-dataset evidence is interpreted at the workflow and interface level. The
shared sequence operated across heterogeneous ICU sources, while predictive
leadership, magnitudes, rankings, variables, measurement processes, ontologies,
and graph assumptions remained dataset specific. Similarly named states are not
treated as semantically identical; results remain separate and unpooled.
Preserving these distinctions is framed as a design strength, without claiming
pooled clinical replication.

### Estimator triangulation and CausalPFN

The accepted 19/19 CausalForestDML--LinearDML direction result is interpreted as
within-design robustness to different DML final-stage forms. The accepted 18/19
all-three result keeps CausalPFN prominent as a promising complementary
estimator for the resources. PhysioNet shock remains the sole explicit exception
and is treated as useful model/support-sensitivity evidence motivating targeted
analysis of proxy definition, support, adjustment assumptions, and estimator
behavior.

The text states that direction agreement neither establishes equal magnitudes
nor proves causal identification and should not replace uncertainty analysis.
CausalPFN's less complete archived estimator-specific sensitivity and
permutation package is stated once, without obscuring its broad concordance. No
unsupported CausalPFN architecture, training, theory, novelty, or citation claim
was introduced.

### LLM-assisted design and future research

The LLM is presented as a structured design-time aid that translates clinical
and causal reasoning into inspectable proposals. Project selection and encoded
source remain authoritative, and deterministic patient-level execution is kept
separate. The text explicitly denies construct-validation and patient-level
effect-estimation roles for the LLM.

Prioritized future work includes clinician evaluation of proxy constructs;
multi-expert and multi-LLM comparisons; an isolated LLM design-layer ablation;
alternative proxy ontologies, DAGs, and adjustment sets; stronger repeated-run
uncertainty evaluation; richer CausalPFN diagnostics; and external validation on
additional datasets. These are research priorities, not claims of completed
experiments.

### Centralized limitations

One concentrated passage covers all required boundaries:

- transparent proxy constructs are not chart-adjudicated phenotypes, but their
  deterministic definitions and lineage support direct replacement and testing;
- project DAGs do not prove intervention validity, and observational estimates
  remain vulnerable to unmeasured confounding and unresolved identification;
- repeated-run uncertainty and diagnostic coverage are incomplete for some
  archived comparisons;
- CausalPFN has a smaller archived diagnostic envelope than the DML estimators;
- exact historical producing revisions, configurations, and
  checkpoint-to-export lineage remain incomplete;
- current-runtime validation and anonymous-release readiness remain separately
  gated;
- restricted source-data access and absent external clinical validation limit
  immediate generalization; and
- the LLM design layer lacks an isolated ablation.

Each major limitation is paired with a resource feature or next experiment.
Defensive language is not scattered through the earlier Discussion paragraphs.

### Conclusion checks

The Conclusion states what CliniCause constructs, names MIMIC-III and PhysioNet
2012, summarizes structural/cohort/provenance/analytical validation, preserves
the value of broad DML/CausalPFN triangulation, and closes on the research agenda
enabled by transparent resources. It introduces no new scientific number,
citation, experiment, public-release claim, clinical recommendation, or other
new claim. It is release neutral.

## Evidence, citation, and claim checks

`paper_evidence_map.md` now records the P6 baseline and claims C71--C83 with
exact manuscript locations, highest-authority sources, support status, and local
qualifications. The canonical-plan path/version/hash was updated to Version 1.1.
No new bibliography entry or citation was added.

No new numerical result was introduced. The only scientific counts in
Discussion are the accepted P5 19/19 and 18/19 mappings, used with their frozen
meaning. CausalPFN remains prominent. No unsupported causal, clinical, LLM, or
release claim was added. Discussion interprets headline patterns and reuse
rather than repeating Results cell by cell. Conclusion introduces no new claim.

Open gates remain:

- `TODO-EVIDENCE G-EVD-01`: verified primary CausalPFN bibliography entry;
- `TODO-EVIDENCE G-EVD-02`: producing revisions/configurations and predictive
  split/checkpoint-to-export lineage;
- `TODO-RUNTIME G-RUN-01/G-RUN-02`: current test execution and a complete
  integrated current-revision rerun;
- `TODO-RELEASE G-REL-01`: anonymous package/URL, license, access instructions,
  and final contents;
- `TODO-HUMAN G-HUM-01/G-HUM-02`: scientific framing, authorship, ethics,
  governance, and anonymity decisions; and
- `TODO-AAAI G-AAAI-01`: final-day verification of mutable AAAI-27 rules.

These gates do not block this bounded interpretation draft because the affected
claims remain excluded or explicitly qualified.

## Build and validation

| Field | Result |
|---|---|
| Build command | `env TEXINPUTS=AuthorKit27: BSTINPUTS=AuthorKit27: BIBINPUTS=../literature/metadata: latexmk -pdf -interaction=nonstopmode -halt-on-error paper.tex` |
| Build result | Success; `latexmk` exit code 0; citations and references resolved |
| Output | `thesis-writing/paper-aaai/paper.pdf` |
| PDF SHA-256 | `3c1d90db329e51cce2c8b4d9b32d1c63ecb5bf7b7e0965ecd479eb894acb6c0c` |
| PDF page count | 7 |
| PDF page size | 612 x 792 pt, US Letter |
| Layout | Official anonymous AAAI two-column submission layout |
| Fonts | Embedded/subset Type 1 and CID TrueType; no Type 3 font |

The final log contains no undefined citation, undefined reference, multiply
defined label, missing file, horizontal overfull box, or fatal warning. The
known 33.21437 pt first-page overfull vertical-box diagnostic from P3--P5
persists; full-page inspection again shows no clipping, overlap, margin/gutter
breach, or readability defect. Underfull diagnostics are ordinary
paragraph/table justification and the expected page-5 column fill around the
full-width Results floats.

All seven pages were rendered at 120 dpi and inspected at full-page resolution.
Pages 5--6 were additionally checked against extracted coordinates. Table 2 and
Figure 2 remain wholly before Section 6 under the existing float barrier; no
Results float crosses into Discussion. Discussion/Conclusion headings,
two-column flow, margins, gutter, captions, and references are clear. No text or
figure is clipped. Page 7 contains only the final reference continuation. The
anonymous author block, page-number suppression, and US Letter layout remain
intact.

## Protection, repository state, and readiness

The protected Version 1.1 plan hash remains
`8df13e88892da8cd0d78df33e0b7a997983d95f99222de0eb9605426e905b1c1`.
The pre-existing modified `prompt.txt` and untracked plan were not edited by P6.
No protected thesis, checked result, reproducibility, literature, bibliography,
planning, code, test, data, run, Author Kit, figure, table, or earlier-stage
report file was changed. `git diff --check` passes.

HEAD remains the accepted P5 commit. No file was staged, committed, pushed,
reset, restored, reverted, cleaned, or deleted. Repository cleanup remains
deferred by user decision.

The Discussion and Conclusion meet the scientific, structural, evidence,
release-neutrality, layout, and reporting requirements for the revised P6
stage.

READY FOR STAGE P7 — INTERPRETATION AND CONCLUSION DRAFTED
